BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 19, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 2017

View Archived Issues

Telix announces product development partnership with Therapeia for ACD-101

Read More

Innovate UK grant supports Ubiquigent's development of compound libraries targeting DUB enzymes

Read More

Merck & Co. describes novel PDE2A inhibitors

Read More

Immuron begins mechanism of action studies on IMM-124E for NASH

Read More

Bristol-Myers Squibb patents novel indoleamine 2,3-dioxygenase 1 inhibitors

Read More

The University of Michigan discovers GRK2, GRK5 inhibitors

Read More

Janssen discloses new sulfamoylarylamide derivatives for HBV infection

Read More

Genentech and Roche present novel PI3Kalpha and PI3Kdelta inhibitors

Read More

D9-ivacaftor granted U.S. orphan designation for cystic fibrosis

Read More

REGN-2477 receives FDA orphan designation for fibrodysplasia ossificans progressiva

Read More

Corvus Pharmaceuticals presents overview of pipeline

Read More

Zydus Cadila acquires Sentynl Therapeutics

Read More

Voyager Therapeutics provides update on phase Ib study of gene therapy for Parkinson's

Read More

Minerva Neurosciences gives results from additional data analyses on phase IIb MIN-101 study

Read More

Takeda identifies the first GPX4 inhibitory peptide

Read More

Simmiparib demonstrates favorable pharmacokinetic profile and in vivo anticancer activity

Read More

First patient dosed in phase Ib study of OncoMed's brontictuzumab

Read More

NeuroVive signs preclinical collaboration agreement with CHOP for mitochondrial disorders

Read More

Gilead Sciences' MAA for sofosbuvir/velpatasvir/voxilaprevir validated by EMA

Read More

ADI-PEG20 well tolerated with nab-paclitaxel and gemcitabine in pancreatic cancer trial

Read More

Actelion reports findings from phase III study of macitentan in PAH due to Eisenmenger syndrome

Read More

Trametinib studied with 5-fluorouracil and chemoradiation in rectal cancer trial

Read More

New Innovate UK award supports Cypralis' development of cyclophilin D inhibitors

Read More

Jazz Pharmaceuticals reviews pipeline outlook

Read More

Incyte advances INCB-050465 into phase II for relapsed or refractory DLBCL

Read More

NIAID studies Zika virus DNA vaccine in phase I trial

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing